Abstract
Prenatal screening has undergone a profound transformation with the emergence of Non-Invasive Prenatal Testing (NIPT), a technology that analyzes cell-free fetal DNA (cffDNA) in maternal blood to detect common chromosomal abnormalities. Compared to traditional biochemical and ultrasound-based screening, NIPT offers markedly higher accuracy, earlier detection, and reduced procedural risk, representing a true paradigm shift in prenatal care. This narrative review synthesizes current evidence on the clinical performance, technological evolution, and ethical implications of NIPT within modern obstetric practice. Findings indicate that NIPT demonstrates exceptional sensitivity and specificity for trisomy 21, with strong performance for trisomy's 18 and 13 and promising application to sex chromosome aneuploidies. Its adoption has led to a significant reduction in invasive diagnostic procedures such as amniocentesis, thereby enhancing maternal safety and psychological comfort. Recent advancements-including SNP-based and fragmentomics-enhanced sequencing, artificial intelligence integration, and combined screening approaches-have further expanded NIPT's precision and potential scope. However, challenges persist regarding test accessibility, cost-effectiveness, and the interpretation of complex results from expanded panels. Beyond its clinical and technological merits, the review underscores the importance of addressing ethical, legal, and social concerns such as informed consent, privacy protection, and equitable access, particularly as direct-to-consumer models emerge. Ultimately, NIPT stands as a transformative innovation in reproductive medicine, offering a safer and more individualized approach to prenatal screening. Its continued success will depend on the establishment of robust ethical frameworks and equitable implementation strategies to ensure that advances in genetic technology translate into meaningful and responsible improvements in maternal-fetal care.